Our Science
Boundary-breaking protein degradation
EpiBiologics is bringing protein degradation to membrane and extracellular proteins – the 40% of the proteome that is currently unaddressed by this powerful degradation technology. Our pioneering EpiTAC platform leverages bispecific antibodies and a novel atlas of tissue-specific degrader receptors, enabling a new therapeutic modality with a wide range of applications, including oncology, immunology and inflammation, neurodegeneration and metabolism. EpiTACs make it possible to target currently intractable molecules and to increase the therapeutic index through tissue selectivity. EpiTAC’s bispecific antibody format ensures good pharmacological properties and scalable manufacturing, paving a clear path to the clinic.
EpiTAC Platform: Degradation for any indication
Our modular bispecific EpiTAC platform takes advantage of multiple strategies to achieve cell- and tissue-selective targeted protein degradation of extracellular antigens. One arm of the therapeutic binds the protein target of interest and the other arm leverages our diverse EpiAtlas repertoire of tissue-enriched degrader receptors. EpiTAC degraders work at substoichometric levels and amplify the biologic impact of degradation by disrupting target scaffolding function and downstream signaling events.
MULTIPLE STRATEGIES FOR TISSUE-SPECIFIC TARGETED PROTEIN DEGRADATION
Proteasomal degradation via cell-surface ubiquitin ligases
AbTACs bring together the protein of interest and transmembrane E3 ligases to drive ubiquitination and degradation of membrane proteins by the proteasome.
Lysosomal degradation via cell-surface cytokine or chemokine receptors
KineTACs leverage the natural internalization process driven by chemokine or cytokine receptors, binding the receptor via the native ligand to drive internalization and lysosomal degradation of soluble and membrane targets.
Lysosomal degradation via tissue-enriched internalizing receptors
The novel TrainTAC degrader utilizes a broad array of internalizing receptors to deliver membrane and soluble extracellular proteins for lysosomal degradation.
Unparalleled diversity.
Unparalleled selectivity.
EpiAtlas platform:
Our EpiTACs leverage an EpiAtlas of over 270 degrader arms that target transmembrane ligases, cytokine and chemokine receptors and internalizing receptors. This diverse library allows us to optimally pair the target of interest with a degrader receptor that achieves cell- or tissue-specificity, enabling an emerging pipeline across a broad range of therapeutic areas.
TARGET AND DEGRADER PAIRS OPTIMIZED THROUGH BIOINFORMATICS AND BIOLOGICAL INSIGHTS
